MedTrace Logo

Plexin B2 Gene Expression and Polymorphisms in Psoriasis

NCT05184348 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-09-21

No results posted yet for this study

Summary

Patients will be randomly assigned (1:1:1 ) either to ; NB-UVB photo-therapy alone , Acitretin therapy alone or NB-UVB photo-therapy combined with Acitretin therapy randomization will be done by closed envelopes . investigator will be blinded to study drug assignment , while patients and data interpreter will not be masked to study drug assignment.

Conditions

  • Psoriasis Vulgaris

Interventions

RADIATION

Narrow band Ultraviolet B phototherapy group

3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.

DRUG

Acitretin group

dose of 0.5-1 mg per kg per day orally for 3 month.

COMBINATION_PRODUCT

Acitretin plus Narrow band Ultraviolet B phototherapy group

Acitretin in dose of 0.5-1 mg per kg per day orally plus Narrow band Ultraviolet B phototherapy 3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.

Sponsors & Collaborators

  • South Valley University

    lead OTHER

Principal Investigators

  • Eisa Hegazy, Prof. · Faculty of Medicine, South Valley University, Egypt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
24 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2023-01-30
Completion
2023-03-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05184348 on ClinicalTrials.gov